68 posts
Semaglutide in Indian Teens Cuts Weight 17.2% in Real-World Peptide Data
A 40-patient Indian retrospective study links once-weekly semaglutide to a 17.2% mean weight reduction in adolescents, with implications for GLP-1 clinics and peptide supply chains.
Oct 26, 2026MHRA Probes UK Peptide Clinics Over Unlawful Medicinal Claims
The MHRA is investigating whether UK peptide clinics are making unlawful medicinal claims for unregulated, experimental peptides, a case with compliance and supply-chain implications for the sector.
Oct 26, 2026Viking Therapeutics Adds $548M Raise to $502M Cash for Oral GLP-1/GIP VK2735
Viking Therapeutics reported $502M in cash at June 30 and a ~$548M September financing for its metabolic pipeline, with VK2735 framed as a conditional oral GLP-1/GIP bet.
Oct 25, 2026GLP-1 Gender Gap Widens as Women Outpace Men in Obesity Prescriptions
US prescribing data show about 3% of eligible women received semaglutide or tirzepatide for obesity versus 1.2% of men, a gap that widened after 2021 and shapes peptide therapy demand.
Oct 25, 2026Tirzepatide Recall: 22 Compounded GLP-1 Vials Pulled Over Sterility Assurance
Apothecary Pharma recalled 22 vials of compounded tirzepatide over sterility assurance; the FDA classified it Class II after a December warning letter on labeling and sterile practices.
Oct 25, 2026Wegovy Pill vs Shot: Same Semaglutide, New Dosing Calculus for Peptide Clinics
The FDA-approved Wegovy pill carries the same semaglutide as the injection but requires strict daily dosing, shifting the clinical and supply-chain calculus for peptide therapy operators.
Oct 25, 2026FDA Panel Backs Easing BPC-157 and KPV Rules: What Peptide Clinics Face
An FDA advisory panel recommended easing restrictions on BPC-157 and KPV, a conditional step toward compounding availability that leaves clinical evidence gaps unresolved.
Oct 24, 2026Injectable Peptides Sold as ‘Glow Up Potion’ Draw Expert Warnings on Unapproved Use
Experts warn that injectable peptides promoted online as a 'glow up potion' are unapproved research products with unknown risks, as RFK Jr claims he will approve about 14 peptide drugs.
Oct 24, 2026Peptide Pen Cartridge Filling Video Spotlights Device Supply Chain Gap
A 2024 YouTube video illustrates filling a 3ML cartridge for reusable peptide injection pens, raising device handling and documentation questions for the peptide supply chain.
Oct 24, 2026Low-Dose Semaglutide Cuts Heart Stiffness in Animal HFpEF Study, Cedars-Sinai Reports
A Cedars-Sinai-led animal study reports low-dose semaglutide reduced heart stiffness in an HFpEF-like model without weight loss, with human relevance still unproven.
Oct 23, 2026Lilly’s GLP-1 Sales Hit $27.7B as Q3 Earnings Test Oral Foundayo
Eli Lilly reports Q3 2026 results Oct. 29 with Mounjaro and Zepbound at $27.7B in H1 sales. Here is what the numbers mean for peptide supply and clinics.
Oct 23, 2026Georgia Clinics Market Unapproved Retatrutide, Lilly Warns of Illegal Sales
An AJC investigation found at least 17 Georgia medical facilities advertising products marketed as retatrutide, an unapproved Lilly drug. Lilly says sales outside its trials are illegal.
Oct 23, 2026